Chauvette Vincent, Mazine Amine, Bouchard Denis
Division of Cardiac Surgery, University of Montreal, Montreal, QC, Canada.
Division of Cardiac Surgery, University of Toronto, Toronto, ON, Canada.
J Vis Surg. 2018 May 3;4:87. doi: 10.21037/jovs.2018.03.10. eCollection 2018.
Aortic stenosis has traditionally been addressed with surgical aortic valve replacement (AVR). In recent years, several technologies have emerged as alternative treatment methods for aortic valve disease. Among them, the Perceval (LivaNova, London, UK) is a sutureless valve that has been used in clinical practice for over 10 years. It has been implanted in over 20,000 patients worldwide. With nearly 600 Perceval implants since 2011, the Montreal Heart Institute has developed a worldwide expertise with this technology. In this article, we provide an overview of the clinical data currently available in the literature and discuss the lessons we have learned from our experience with the Perceval prosthesis.
传统上，主动脉瓣狭窄通过外科主动脉瓣置换术（AVR）进行治疗。近年来，出现了几种技术作为主动脉瓣疾病的替代治疗方法。其中，Perceval（英国伦敦LivaNova公司）是一种无缝合瓣膜，已在临床实践中使用了10多年。它已在全球超过20000名患者中植入。自2011年以来，蒙特利尔心脏研究所已进行了近600例Perceval植入手术，在这项技术方面积累了全球范围内的专业经验。在本文中，我们概述了目前文献中可用的临床数据，并讨论了我们从使用Perceval人工瓣膜的经验中学到的经验教训。
